<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2020 Workiva--><!--r:16ddbe16-9559-4973-890a-6eb7a86498c9,g:2a7142b1-2b71-418f-b8ed-3202de2afecd,d:0376518780f948efb2b6903920eecb0d--><html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>anab-20201023</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="icc3fc52eb69743f1beeb716f10b11185_D20201023-20201023" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjAzNzY1MTg3ODBmOTQ4ZWZiMmI2OTAzOTIwZWVjYjBkL3NlYzowMzc2NTE4NzgwZjk0OGVmYjJiNjkwMzkyMGVlY2IwZF80L2ZyYWc6YTQyODg2ODUwMjYwNGRjNDgyMWM3ZjVlNGE5Y2M0NGMvdGFibGU6M2FmMDU4M2QzYjAwNGVmMmI2YTc0MDFjMTk2M2NiNzYvdGFibGVyYW5nZTozYWYwNTgzZDNiMDA0ZWYyYjZhNzQwMWMxOTYzY2I3Nl8yLTEtMS0xLTA_33fd920c-35a2-485d-bce2-2e517775ed4a">0001370053</ix:nonNumeric><ix:nonNumeric contextRef="icc3fc52eb69743f1beeb716f10b11185_D20201023-20201023" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjAzNzY1MTg3ODBmOTQ4ZWZiMmI2OTAzOTIwZWVjYjBkL3NlYzowMzc2NTE4NzgwZjk0OGVmYjJiNjkwMzkyMGVlY2IwZF80L2ZyYWc6YTQyODg2ODUwMjYwNGRjNDgyMWM3ZjVlNGE5Y2M0NGMvdGFibGU6M2FmMDU4M2QzYjAwNGVmMmI2YTc0MDFjMTk2M2NiNzYvdGFibGVyYW5nZTozYWYwNTgzZDNiMDA0ZWYyYjZhNzQwMWMxOTYzY2I3Nl81LTEtMS0xLTA_188ca859-56c1-4184-8f48-4d7c56521ee2">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="anab-20201023.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i36d368ebe6514859bc2e01f439949a4f_D20200810-20200810"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-10</xbrli:startDate><xbrli:endDate>2020-08-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc3fc52eb69743f1beeb716f10b11185_D20201023-20201023"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-23</xbrli:startDate><xbrli:endDate>2020-10-23</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i0376518780f948efb2b6903920eecb0d_1"></div><div style="min-height:72pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">UNITED STATES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">WASHINGTON, D.C. 20549</span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">FORM <ix:nonNumeric contextRef="i36d368ebe6514859bc2e01f439949a4f_D20200810-20200810" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjAzNzY1MTg3ODBmOTQ4ZWZiMmI2OTAzOTIwZWVjYjBkL3NlYzowMzc2NTE4NzgwZjk0OGVmYjJiNjkwMzkyMGVlY2IwZF8xL2ZyYWc6MjE4ZTE4YWU3ZmZmNDllODg1MzNkNmQ4MTkzNGQyZDEvdGV4dHJlZ2lvbjoyMThlMThhZTdmZmY0OWU4ODUzM2Q2ZDgxOTM0ZDJkMV8xNzU3_71527e4d-0261-4af0-ae01-6cbac03a41a7">8-K</ix:nonNumeric></span></div><div><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">CURRENT REPORT PURSUANT TO</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">SECTION 13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">Date of Report: <ix:nonNumeric contextRef="icc3fc52eb69743f1beeb716f10b11185_D20201023-20201023" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjAzNzY1MTg3ODBmOTQ4ZWZiMmI2OTAzOTIwZWVjYjBkL3NlYzowMzc2NTE4NzgwZjk0OGVmYjJiNjkwMzkyMGVlY2IwZF8xL2ZyYWc6MjE4ZTE4YWU3ZmZmNDllODg1MzNkNmQ4MTkzNGQyZDEvdGV4dHJlZ2lvbjoyMThlMThhZTdmZmY0OWU4ODUzM2Q2ZDgxOTM0ZDJkMV8xOTE_7dc99d90-ad53-4ec7-a1c2-8926ceb3a983">October 23, 2020</ix:nonNumeric> </span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">(Date of earliest event reported)</span></div><div><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="icc3fc52eb69743f1beeb716f10b11185_D20201023-20201023" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjAzNzY1MTg3ODBmOTQ4ZWZiMmI2OTAzOTIwZWVjYjBkL3NlYzowMzc2NTE4NzgwZjk0OGVmYjJiNjkwMzkyMGVlY2IwZF8xL2ZyYWc6MjE4ZTE4YWU3ZmZmNDllODg1MzNkNmQ4MTkzNGQyZDEvdGV4dHJlZ2lvbjoyMThlMThhZTdmZmY0OWU4ODUzM2Q2ZDgxOTM0ZDJkMV8xNzYz_e84f182c-0732-4b71-88e2-3b6dcacf4686">ANAPTYSBIO, INC</ix:nonNumeric>.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">(Exact Name of Registrant as Specified in Its Charter)</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.857%;"><tr><td style="width:1.0%;"></td><td style="width:33.707%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:29.855%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:33.138%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:11pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="icc3fc52eb69743f1beeb716f10b11185_D20201023-20201023" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjAzNzY1MTg3ODBmOTQ4ZWZiMmI2OTAzOTIwZWVjYjBkL3NlYzowMzc2NTE4NzgwZjk0OGVmYjJiNjkwMzkyMGVlY2IwZF8xL2ZyYWc6MjE4ZTE4YWU3ZmZmNDllODg1MzNkNmQ4MTkzNGQyZDEvdGFibGU6N2QzZjQ2M2ViNzQwNDlmNmJkODEyZWRmZGI3MzAzYWIvdGFibGVyYW5nZTo3ZDNmNDYzZWI3NDA0OWY2YmQ4MTJlZGZkYjczMDNhYl8wLTAtMS0xLTA_6480ee6f-c6b5-4984-82e4-325dcac4f0a5">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:11pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="icc3fc52eb69743f1beeb716f10b11185_D20201023-20201023" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjAzNzY1MTg3ODBmOTQ4ZWZiMmI2OTAzOTIwZWVjYjBkL3NlYzowMzc2NTE4NzgwZjk0OGVmYjJiNjkwMzkyMGVlY2IwZF8xL2ZyYWc6MjE4ZTE4YWU3ZmZmNDllODg1MzNkNmQ4MTkzNGQyZDEvdGFibGU6N2QzZjQ2M2ViNzQwNDlmNmJkODEyZWRmZGI3MzAzYWIvdGFibGVyYW5nZTo3ZDNmNDYzZWI3NDA0OWY2YmQ4MTJlZGZkYjczMDNhYl8wLTEtMS0xLTA_ee6a73b7-e62b-4f25-b08f-4d4376fec325">001-37985</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:11pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="icc3fc52eb69743f1beeb716f10b11185_D20201023-20201023" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjAzNzY1MTg3ODBmOTQ4ZWZiMmI2OTAzOTIwZWVjYjBkL3NlYzowMzc2NTE4NzgwZjk0OGVmYjJiNjkwMzkyMGVlY2IwZF8xL2ZyYWc6MjE4ZTE4YWU3ZmZmNDllODg1MzNkNmQ4MTkzNGQyZDEvdGFibGU6N2QzZjQ2M2ViNzQwNDlmNmJkODEyZWRmZGI3MzAzYWIvdGFibGVyYW5nZTo3ZDNmNDYzZWI3NDA0OWY2YmQ4MTJlZGZkYjczMDNhYl8wLTItMS0xLTA_9dfe7992-c9b0-46d4-a50f-36b60f6f8eb2">20-3828755</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:11pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(State or Other Jurisdiction of Incorporation)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:11pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Commission File Number)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:11pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(IRS Employer Identification No.)</span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="icc3fc52eb69743f1beeb716f10b11185_D20201023-20201023" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjAzNzY1MTg3ODBmOTQ4ZWZiMmI2OTAzOTIwZWVjYjBkL3NlYzowMzc2NTE4NzgwZjk0OGVmYjJiNjkwMzkyMGVlY2IwZF8xL2ZyYWc6MjE4ZTE4YWU3ZmZmNDllODg1MzNkNmQ4MTkzNGQyZDEvdGV4dHJlZ2lvbjoyMThlMThhZTdmZmY0OWU4ODUzM2Q2ZDgxOTM0ZDJkMV8xNzY5_572effba-399f-47c6-acf4-4ee75be7de30">10421 Pacific Center Court</ix:nonNumeric>, <ix:nonNumeric contextRef="icc3fc52eb69743f1beeb716f10b11185_D20201023-20201023" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjAzNzY1MTg3ODBmOTQ4ZWZiMmI2OTAzOTIwZWVjYjBkL3NlYzowMzc2NTE4NzgwZjk0OGVmYjJiNjkwMzkyMGVlY2IwZF8xL2ZyYWc6MjE4ZTE4YWU3ZmZmNDllODg1MzNkNmQ4MTkzNGQyZDEvdGV4dHJlZ2lvbjoyMThlMThhZTdmZmY0OWU4ODUzM2Q2ZDgxOTM0ZDJkMV8xNzU4_87e47c11-1676-4ed4-9668-9f3f963c6b4b">Suite 200</ix:nonNumeric> </span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="icc3fc52eb69743f1beeb716f10b11185_D20201023-20201023" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjAzNzY1MTg3ODBmOTQ4ZWZiMmI2OTAzOTIwZWVjYjBkL3NlYzowMzc2NTE4NzgwZjk0OGVmYjJiNjkwMzkyMGVlY2IwZF8xL2ZyYWc6MjE4ZTE4YWU3ZmZmNDllODg1MzNkNmQ4MTkzNGQyZDEvdGV4dHJlZ2lvbjoyMThlMThhZTdmZmY0OWU4ODUzM2Q2ZDgxOTM0ZDJkMV8xNzU5_c25fea9c-6141-439b-a57c-bab754c3ee92">San Diego</ix:nonNumeric>, <ix:nonNumeric contextRef="icc3fc52eb69743f1beeb716f10b11185_D20201023-20201023" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjAzNzY1MTg3ODBmOTQ4ZWZiMmI2OTAzOTIwZWVjYjBkL3NlYzowMzc2NTE4NzgwZjk0OGVmYjJiNjkwMzkyMGVlY2IwZF8xL2ZyYWc6MjE4ZTE4YWU3ZmZmNDllODg1MzNkNmQ4MTkzNGQyZDEvdGV4dHJlZ2lvbjoyMThlMThhZTdmZmY0OWU4ODUzM2Q2ZDgxOTM0ZDJkMV8xNzYw_f8dc00c8-4c88-488b-86a2-97294cbc7df9">CA</ix:nonNumeric>  <ix:nonNumeric contextRef="icc3fc52eb69743f1beeb716f10b11185_D20201023-20201023" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjAzNzY1MTg3ODBmOTQ4ZWZiMmI2OTAzOTIwZWVjYjBkL3NlYzowMzc2NTE4NzgwZjk0OGVmYjJiNjkwMzkyMGVlY2IwZF8xL2ZyYWc6MjE4ZTE4YWU3ZmZmNDllODg1MzNkNmQ4MTkzNGQyZDEvdGV4dHJlZ2lvbjoyMThlMThhZTdmZmY0OWU4ODUzM2Q2ZDgxOTM0ZDJkMV8xNzYx_b80532d8-0845-4ef4-9b41-474ed261af22">92121</ix:nonNumeric> </span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">(Address of Principal Executive Offices, and Zip Code)</span></div><div><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">(<ix:nonNumeric contextRef="icc3fc52eb69743f1beeb716f10b11185_D20201023-20201023" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjAzNzY1MTg3ODBmOTQ4ZWZiMmI2OTAzOTIwZWVjYjBkL3NlYzowMzc2NTE4NzgwZjk0OGVmYjJiNjkwMzkyMGVlY2IwZF8xL2ZyYWc6MjE4ZTE4YWU3ZmZmNDllODg1MzNkNmQ4MTkzNGQyZDEvdGV4dHJlZ2lvbjoyMThlMThhZTdmZmY0OWU4ODUzM2Q2ZDgxOTM0ZDJkMV8xNzU1_47afa5bd-4e4a-41e4-a40f-2024e3346faa">858</ix:nonNumeric>) <ix:nonNumeric contextRef="icc3fc52eb69743f1beeb716f10b11185_D20201023-20201023" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjAzNzY1MTg3ODBmOTQ4ZWZiMmI2OTAzOTIwZWVjYjBkL3NlYzowMzc2NTE4NzgwZjk0OGVmYjJiNjkwMzkyMGVlY2IwZF8xL2ZyYWc6MjE4ZTE4YWU3ZmZmNDllODg1MzNkNmQ4MTkzNGQyZDEvdGV4dHJlZ2lvbjoyMThlMThhZTdmZmY0OWU4ODUzM2Q2ZDgxOTM0ZDJkMV8xNzY0_0f95e2a7-3ec9-407e-a49e-c05b53c08017">362-6295</ix:nonNumeric> </span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">(Registrant&#8217;s Telephone Number, Including Area Code)</span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">Not Applicable</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">(Former name or former address, if changed since last report.)</span></div><div style="text-align:center;"><span><br/></span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Check the appropriate box below if the Form&#160;8&#8209;K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="icc3fc52eb69743f1beeb716f10b11185_D20201023-20201023" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="id3VybDovL2RvY3MudjEvZG9jOjAzNzY1MTg3ODBmOTQ4ZWZiMmI2OTAzOTIwZWVjYjBkL3NlYzowMzc2NTE4NzgwZjk0OGVmYjJiNjkwMzkyMGVlY2IwZF8xL2ZyYWc6MjE4ZTE4YWU3ZmZmNDllODg1MzNkNmQ4MTkzNGQyZDEvdGV4dHJlZ2lvbjoyMThlMThhZTdmZmY0OWU4ODUzM2Q2ZDgxOTM0ZDJkMV8xNzY1_fb1a51b0-287e-47f9-a7d7-a4794e6db053">&#9744;</ix:nonNumeric></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="icc3fc52eb69743f1beeb716f10b11185_D20201023-20201023" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="id3VybDovL2RvY3MudjEvZG9jOjAzNzY1MTg3ODBmOTQ4ZWZiMmI2OTAzOTIwZWVjYjBkL3NlYzowMzc2NTE4NzgwZjk0OGVmYjJiNjkwMzkyMGVlY2IwZF8xL2ZyYWc6MjE4ZTE4YWU3ZmZmNDllODg1MzNkNmQ4MTkzNGQyZDEvdGV4dHJlZ2lvbjoyMThlMThhZTdmZmY0OWU4ODUzM2Q2ZDgxOTM0ZDJkMV8xNzY2_6986df92-8075-422b-bf58-0f21c1ca5941">&#9744;</ix:nonNumeric></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Soliciting material pursuant to Rule&#160;14a&#8209;12 under the Exchange Act (17 CFR 240.14a&#8209;12)</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="icc3fc52eb69743f1beeb716f10b11185_D20201023-20201023" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="id3VybDovL2RvY3MudjEvZG9jOjAzNzY1MTg3ODBmOTQ4ZWZiMmI2OTAzOTIwZWVjYjBkL3NlYzowMzc2NTE4NzgwZjk0OGVmYjJiNjkwMzkyMGVlY2IwZF8xL2ZyYWc6MjE4ZTE4YWU3ZmZmNDllODg1MzNkNmQ4MTkzNGQyZDEvdGV4dHJlZ2lvbjoyMThlMThhZTdmZmY0OWU4ODUzM2Q2ZDgxOTM0ZDJkMV8xNzY3_038276fc-e6ed-40a0-b03b-9c5b91e4d100">&#9744;</ix:nonNumeric></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pre&#8209;commencement communications pursuant to Rule&#160;14d&#8209;2(b)&#160;under the Exchange Act (17 CFR 240.14d&#8209;2(b))</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="icc3fc52eb69743f1beeb716f10b11185_D20201023-20201023" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="id3VybDovL2RvY3MudjEvZG9jOjAzNzY1MTg3ODBmOTQ4ZWZiMmI2OTAzOTIwZWVjYjBkL3NlYzowMzc2NTE4NzgwZjk0OGVmYjJiNjkwMzkyMGVlY2IwZF8xL2ZyYWc6MjE4ZTE4YWU3ZmZmNDllODg1MzNkNmQ4MTkzNGQyZDEvdGV4dHJlZ2lvbjoyMThlMThhZTdmZmY0OWU4ODUzM2Q2ZDgxOTM0ZDJkMV8xNzcw_5a2cad86-160e-4248-9508-b25381a68ba3">&#9744;</ix:nonNumeric></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pre&#8209;commencement communications pursuant to Rule&#160;13e&#8209;4(c)&#160;under the Exchange Act (17 CFR 240.13e&#8209;4(c))</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.866%;"><tr><td style="width:1.0%;"></td><td style="width:35.370%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:17.870%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:43.460%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;margin-bottom:2.2pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Title of each class</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;margin-bottom:2.2pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Trading Symbol(s)</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><div style="text-align:center;margin-bottom:2.2pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Name of each exchange on which registered</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;margin-bottom:2.2pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><ix:nonNumeric contextRef="icc3fc52eb69743f1beeb716f10b11185_D20201023-20201023" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjAzNzY1MTg3ODBmOTQ4ZWZiMmI2OTAzOTIwZWVjYjBkL3NlYzowMzc2NTE4NzgwZjk0OGVmYjJiNjkwMzkyMGVlY2IwZF8xL2ZyYWc6MjE4ZTE4YWU3ZmZmNDllODg1MzNkNmQ4MTkzNGQyZDEvdGFibGU6MzhiYmYwODEwNDdlNGE4ZTkyZWUzNjM0NzIxM2E1NTAvdGFibGVyYW5nZTozOGJiZjA4MTA0N2U0YThlOTJlZTM2MzQ3MjEzYTU1MF8xLTAtMS0xLTA_4547ff1b-3d0e-4e29-a397-77bb4896b7f8">Common Stock, par value $0.001 per share</ix:nonNumeric></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;margin-bottom:2.2pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><ix:nonNumeric contextRef="icc3fc52eb69743f1beeb716f10b11185_D20201023-20201023" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjAzNzY1MTg3ODBmOTQ4ZWZiMmI2OTAzOTIwZWVjYjBkL3NlYzowMzc2NTE4NzgwZjk0OGVmYjJiNjkwMzkyMGVlY2IwZF8xL2ZyYWc6MjE4ZTE4YWU3ZmZmNDllODg1MzNkNmQ4MTkzNGQyZDEvdGFibGU6MzhiYmYwODEwNDdlNGE4ZTkyZWUzNjM0NzIxM2E1NTAvdGFibGVyYW5nZTozOGJiZjA4MTA0N2U0YThlOTJlZTM2MzQ3MjEzYTU1MF8xLTEtMS0xLTA_e21a7712-46ad-4c52-98a2-f71698d9dd05">ANAB</ix:nonNumeric></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><div style="text-align:center;margin-bottom:2.2pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><ix:nonNumeric contextRef="icc3fc52eb69743f1beeb716f10b11185_D20201023-20201023" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjAzNzY1MTg3ODBmOTQ4ZWZiMmI2OTAzOTIwZWVjYjBkL3NlYzowMzc2NTE4NzgwZjk0OGVmYjJiNjkwMzkyMGVlY2IwZF8xL2ZyYWc6MjE4ZTE4YWU3ZmZmNDllODg1MzNkNmQ4MTkzNGQyZDEvdGFibGU6MzhiYmYwODEwNDdlNGE4ZTkyZWUzNjM0NzIxM2E1NTAvdGFibGVyYW5nZTozOGJiZjA4MTA0N2U0YThlOTJlZTM2MzQ3MjEzYTU1MF8xLTItMS0xLTA_f3b0a356-cddc-492e-893b-6068483c32b6">The Nasdaq Stock Market LLC</ix:nonNumeric></span></div></td></tr></table></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div style="text-align:right;"><span><br/></span></div><div style="text-align:right;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Emerging growth company</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">   </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="icc3fc52eb69743f1beeb716f10b11185_D20201023-20201023" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjAzNzY1MTg3ODBmOTQ4ZWZiMmI2OTAzOTIwZWVjYjBkL3NlYzowMzc2NTE4NzgwZjk0OGVmYjJiNjkwMzkyMGVlY2IwZF8xL2ZyYWc6MjE4ZTE4YWU3ZmZmNDllODg1MzNkNmQ4MTkzNGQyZDEvdGV4dHJlZ2lvbjoyMThlMThhZTdmZmY0OWU4ODUzM2Q2ZDgxOTM0ZDJkMV8xNzYy_52ee1440-3cff-4991-8928-ee74dfead24e">&#9744;</ix:nonNumeric></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#9744;</span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><span><br/></span></div></div></div><div id="i0376518780f948efb2b6903920eecb0d_7"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:-63pt;padding-left:63pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">Item 1.01 Entry Into a Material Definitive Agreement.    </span></div><div style="text-indent:-63pt;padding-left:63pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">On October 23, 2020, AnaptysBio, Inc. (&#8220;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">AnaptysBio</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#8221;) entered into an amendment (the &#8220;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Amendment</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#8221;) to its Collaboration and Exclusive License Agreement (the &#8220;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Collaboration Agreement</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#8221;) with Tesaro, Inc., and Tesaro Development, Ltd. (together, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">&#8220;Tesaro</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#8221;), each a wholly-owned subsidiary of GlaxoSmithKline (&#8220;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">GSK</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#8221;).  </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Under the Amendment, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">AnaptysBio is entitled to increased royalties upon sales of dostarlimab, an anti-PD-1 antagonist antibody, equal to 8% of Net Sales (as defined in the Collaboration Agreement) below $1 billion and from 12% up to 25% of Net Sales above $1 billion.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">  </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Amendment also provides for </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">a one-time cash payment </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">of $60 million payable to AnaptysBio within 30 days of the date of the Amendment.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">  </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The $1.1 billion in cash milestone payments due under the Collaboration Agreement remain unchanged.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">  </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Tesaro also agreed, starting January 1, 2021, to pay AnaptysBio a 1% royalty on all GSK and Tesaro Net Sales of Zejula, which has received US approval for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy, and is under development for additional cancer indications.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">  </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In addition, on October 23, 2020, AnaptysBio entered into a confidential settlement agreement (the &#8220;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Settlement Agreement</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#8221;) with GSK and Tesaro to resolve the claims previously raised in the notice of breach (the &#8220;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Notice</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#8221;) delivered by AnaptysBio to GSK and Tesaro on August 20, 2020.  Pursuant to the Settlement Agreement, AnaptysBio, GSK and Tesaro agreed to the terms of the Amendment described above</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> and a mutual release of claims relating to the Notice, the Delaware Chancery Court action related to the Notice, the Collaboration Agreement and the obligations of the parties under the Collaboration Agreement. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Pursuant to the terms of the Settlement Agreement, AnaptysBio and Tesaro agreed to enter into the Amendment that provided GSK with freedom to conduct development and commercialization of Zejula in combination with any third-party molecules.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">  </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The foregoing summaries of the Amendment and the Settlement Agreement do not purport to be complete and are qualified in their entirety by reference to the full text of the Amendment, the Collaboration Agreement and the Settlement Agreement.  A copy of the Collaboration Agreement is available as Exhibit 10.9 to AnaptysBio&#8217;s Annual Report on Form 10-K for the year ended December 31, 2019.  Copies of the Amendment and Settlement Agreement will be filed as exhibits to AnaptysBio&#8217;s Annual Report on Form 10-K for the year ended December 31, 2020.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">Forward-Looking Statements</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">This filing contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, the royalties, milestone payments and cash payments payable to the company, the settlement with GSK and Tesaro and related release of claims, and the timing or outcome of any regulatory submission or approval of dostarlimab. Statements including words such as &#8220;plan,&#8221; &#8220;seek,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221; or &#8220;ongoing&#8221; and statements in the future tense are forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements are subject to risks and uncertainties that may cause the company&#8217;s actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties described under the heading &#8220;Risk Factors&#8221; in documents the company files from time to time with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and the company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%;">SIGNATURES</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;"> &#160;&#160;&#160;&#160;  &#160;&#160;&#160;&#160;  &#160;&#160;&#160;&#160;  &#160;&#160;&#160;&#160;  </span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:6.752%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:28.547%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:3.867%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:56.434%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="6" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:11pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">AnaptysBio, Inc.</span></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:11pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date:  October 26, 2020</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:11pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">By:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:11pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">/s/ Eric Loumeau</span></td></tr><tr><td colspan="6" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:11pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Name: Eric Loumeau</span></td></tr><tr><td colspan="6" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:11pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Title: Chief Operating Officer and General Counsel</span></td></tr></table></div><div style="text-align:center;"><span><br/></span></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span><br/></span></div><div style="-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"> </span></div></div></div></body></html>
[{"type": "8-K", "sequence": "1", "filename": "anab-20201023.htm", "description": "8-K", "secsgml_size_bytes": 43129}]
{"company-data": {"conformed-name": "ANAPTYSBIO, INC", "cik": "0001370053", "assigned-sic": "2834", "irs-number": "203828755", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-37985", "film-number": "201259101"}, "business-address": {"street1": "10421 PACIFIC CENTER COURT, SUITE 200", "city": "SAN DIEGO", "state": "CA", "zip": "92121", "phone": "858-362-6295"}, "mail-address": {"street1": "10421 PACIFIC CENTER COURT, SUITE 200", "city": "SAN DIEGO", "state": "CA", "zip": "92121"}, "former-company": [{"former-conformed-name": "ANAPTYSBIO INC", "date-changed": "20080828"}, {"former-conformed-name": "ANAPTYS BIOSCIENCES INC", "date-changed": "20060724"}]}
anab-20201023
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
8-K
CURRENT REPORT PURSUANT TO
SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report:
October 23, 2020
(Date of earliest event reported)
ANAPTYSBIO, INC
.
(Exact Name of Registrant as Specified in Its Charter)
Delaware
001-37985
20-3828755
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
10421 Pacific Center Court
,
Suite 200
San Diego
,
CA
92121
(Address of Principal Executive Offices, and Zip Code)
(
858
)
362-6295
(Registrant's Telephone Number, Including Area Code)
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8‑K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a‑12 under the Exchange Act (17 CFR 240.14a‑12)
☐
Pre‑commencement communications pursuant to Rule 14d‑2(b) under the Exchange Act (17 CFR 240.14d‑2(b))
☐
Pre‑commencement communications pursuant to Rule 13e‑4(c) under the Exchange Act (17 CFR 240.13e‑4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.001 per share
ANAB
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Item 1.01 Entry Into a Material Definitive Agreement.
On October 23, 2020, AnaptysBio, Inc. ("
AnaptysBio
") entered into an amendment (the "
Amendment
") to its Collaboration and Exclusive License Agreement (the "
Collaboration Agreement
") with Tesaro, Inc., and Tesaro Development, Ltd. (together,
"Tesaro
"), each a wholly-owned subsidiary of GlaxoSmithKline ("
GSK
").
Under the Amendment,
AnaptysBio is entitled to increased royalties upon sales of dostarlimab, an anti-PD-1 antagonist antibody, equal to 8% of Net Sales (as defined in the Collaboration Agreement) below $1 billion and from 12% up to 25% of Net Sales above $1 billion.
The Amendment also provides for
a one-time cash payment
of $60 million payable to AnaptysBio within 30 days of the date of the Amendment.
The $1.1 billion in cash milestone payments due under the Collaboration Agreement remain unchanged.
Tesaro also agreed, starting January 1, 2021, to pay AnaptysBio a 1% royalty on all GSK and Tesaro Net Sales of Zejula, which has received US approval for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy, and is under development for additional cancer indications.
In addition, on October 23, 2020, AnaptysBio entered into a confidential settlement agreement (the "
Settlement Agreement
") with GSK and Tesaro to resolve the claims previously raised in the notice of breach (the "
Notice
") delivered by AnaptysBio to GSK and Tesaro on August 20, 2020.  Pursuant to the Settlement Agreement, AnaptysBio, GSK and Tesaro agreed to the terms of the Amendment described above
and a mutual release of claims relating to the Notice, the Delaware Chancery Court action related to the Notice, the Collaboration Agreement and the obligations of the parties under the Collaboration Agreement.
Pursuant to the terms of the Settlement Agreement, AnaptysBio and Tesaro agreed to enter into the Amendment that provided GSK with freedom to conduct development and commercialization of Zejula in combination with any third-party molecules.
The foregoing summaries of the Amendment and the Settlement Agreement do not purport to be complete and are qualified in their entirety by reference to the full text of the Amendment, the Collaboration Agreement and the Settlement Agreement.  A copy of the Collaboration Agreement is available as Exhibit 10.9 to AnaptysBio's Annual Report on Form 10-K for the year ended December 31, 2019.  Copies of the Amendment and Settlement Agreement will be filed as exhibits to AnaptysBio's Annual Report on Form 10-K for the year ended December 31, 2020.
Forward-Looking Statements
This filing contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, the royalties, milestone payments and cash payments payable to the company, the settlement with GSK and Tesaro and related release of claims, and the timing or outcome of any regulatory submission or approval of dostarlimab. Statements including words such as "plan," "seek," "will," "expect," or "ongoing" and statements in the future tense are forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements are subject to risks and uncertainties that may cause the company's actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties described under the heading "Risk Factors" in documents the company files from time to time with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and the company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
AnaptysBio, Inc.
Date:  October 26, 2020
By:
/s/ Eric Loumeau
Name: Eric Loumeau
Title: Chief Operating Officer and General Counsel